Ernexa Therapeutics Inc. (ERNA)
Nasdaq · Healthcare · Biotechnology
$2.70−8.78%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.4M
- 52-week range
- $2.70 – $71.50
- 52-week change
- −91.29%
- EPS (trailing)
- −$13.63
Fiscal year to Dec 2025
- Net income
- −$14.1M
- Diluted EPS
- −$2.24
- Free cash flow
- −$7.0M
From the company’s annual report on SEC EDGAR.
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 5 employees · ernexatx.com